Showing results (181-190 of 1,273) with videos related to
Sort By:
Pageof 128
Clinical Colorectal Cancer|March 28, 2018
Significance of PITX2 Promoter Methylation in Colorectal Carcinoma PrognosisAlexander Semaan, Barbara Uhl, Vittorio Branchi, et al.Clinical Colorectal Cancer|August 8, 2007
The direct effects of anti-vascular endothelial growth factor therapy on tumor cellsChristian Moser, Sven A Lang, Oliver StoeltzingClinical Colorectal Cancer|August 8, 2007
Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicitiesMarwan G Fakih, Mary Ellen Ross, Petr StarostikClinical Colorectal Cancer|July 25, 2008
Lymph node evaluation in early-stage colon cancerAnand Govindarajan, Nancy N BaxterClinical Colorectal Cancer|July 28, 2009
Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004Marilyn Cree, Jon Tonita, Donna Turner, et al.Clinical Colorectal Cancer|July 28, 2009
Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancerRobert Mauritz, Elisa Giovannetti, Ines J Beumer, et al.Clinical Colorectal Cancer|February 11, 2009
Does celecoxib have a role in the treatment of patients with colorectal cancer?Marwan G Fakih, Youcef M RustumClinical Colorectal Cancer|February 11, 2009
Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancerShriya Bhushan, Howard McLeod, Christine M WalkoClinical Colorectal Cancer|February 11, 2009
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumorsJoe J Stephenson, Charles Gregory, Howard Burris, et al.Clinical Colorectal Cancer|February 11, 2009
Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reportsAlan Langerak, George River, Edith Mitchell, et al.Pageof 128